Knockdown of IG20 gene expression renders thyroid cancer cells susceptible to apoptosis

Journal of Clinical Endocrinology and Metabolism

Volumn 94, Issue 4, 2009, Pages 1467-1471

  Subramanian, Mahesh ^a   Pilli, Tania ^b   Bhattacharya, Palash ^a   Pacini, Furio ^b   Nikiforov, Yuri E ^c   Kanteti, Prasad V ^a   Prabhakar, Bellur S ^a,d  

^a UNIVERSITY OF ILLINOIS   (United States)

^b UNIVERSITY OF SIENA   (Italy)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d Department of Microbiology and Immunology ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 8; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANAPLASTIC CARCINOMA; APOPTOSIS; ARTICLE; CANCER CELL; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME DEFICIENCY; FOLLICULAR CARCINOMA; GENE EXPRESSION; GENETIC VARIABILITY; HUMAN; HUMAN CELL; HUMAN TISSUE; INSULINOMA GLUCAGONOMA 20 GENE; KNOCKOUT GENE; ONCOGENE; PRIORITY JOURNAL; RNA SPLICING; THYROID CANCER;

EID: 65249164186     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2008-2378     Document Type: Article

References (20)

1. Davies L, Welch HG 2006 Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA 295:2164-2167
2. Nikiforova MN, Nikiforov YE 2008 Molecular genetics of thyroid cancer: implications for diagnosis, treatment and prognosis. Expert Rev Mol Diagn 8:83-95
3. Al-Zoubi AM, Efimova EV, Kaithamana S, Martinez O, El-Idrissi Mel A, Dogan RE, Prabhakar BS 2001 Contrasting effects of IG20 and its splice isoforms, MADD and DENN-SV, on tumor necrosis factor α-induced apoptosis and activation of caspase-8 and -3. J Biol Chem 276:47202-47211
4. Lim KM, Yeo WS, Chow VT 2004 Antisense abrogation of DENN expression induces apoptosis of leukemia cells in vitro, causes tumor regression in vivo and alters the transcription of genes involved in apoptosis and the cell cycle. Int J Cancer 109:24 -37
5. Li LC, Sheng J, Mulherkar N, Prabhakar BS, Meriggioli MN 2008 Neuronal cell survival and apoptosis are regulated byneural-specific splice variants of the IG20 gene. Cancer Res 68:7352-7361
6. Efimova E, Martinez O, Lokshin A, Arima T, Prabhakar BS 2003 IG20, a MADD splice variant, increases cell susceptibility to γ-irradiation and induces soluble mediators that suppress tumor cell growth. Cancer Res 63:8768-8776
7. EfimovaEV, Al-ZoubiAM,MartinezO, KaithamanaS,LuS,ArimaT, Prabhakar BS 2004 IG20, in contrast to DENN-SV, (MADD splice variants) suppresses tumor cell survival, and enhances their susceptibility to apoptosis and cancer drugs. Oncogene 23:1076-1087
8. Ramaswamy M, Efimova EV, Martinez O, Mulherkar NU, Singh SP, Prabhakar BS 2004 IG20 (MADD splice variant-5), a proapoptotic protein, interacts with DR4/DR5 and enhances TRAIL-induced apoptosis by increasing recruitment of FADD and caspase-8 to the DISC. Oncogene 23:6083-6094
9. Mulherkar N, Ramaswamy M, Mordi DC, Prabhakar BS 2006 MADD/DENNsplice variant of the IG20 gene is necessary and sufficient for cancer cell survival. Oncogene 25:6252-6261
10. Mulherkar N, Prasad KV, Prabhakar BS 2007 MADD/DENN splice variant of the IG20 gene is a negative regulator of caspase-8 activation. Knockdown enhances TRAIL-induced apoptosis of cancer cells. J Biol Chem 282:11715-11721
11. Lee MT, Coburn GA, McClure MO, Cullen BR 2003 Inhibition of human immunodeficiency virus type 1 replication in primary macrophages by using Tat- or CCR5-specific small interfering RNAs expressed from a lentivirus vector. J Virol 77:11964-11972
12. Ogasawara J, Watanabe-Fukunaga R, Adachi M, Matsuzawa A, Kasugai T, Kitamura Y, Itoh N, Suda T, Nagata S 1993 Lethal effect of the anti-Fas antibody in mice. Nature 364:806 -809
13. Ashkenazi A, Dixit VM 1999 Apoptosis control by death and decoy receptors. Curr Opin Cell Biol 11:255-260
14. Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, Blackie C, Chang L, McMurtrey AE, Hebert A, DeForge L, Koumenis IL, Lewis D, Harris L, Bussiere J, KoeppenH, ShahrokhZ, Schwall RH1999 Safetyand antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 104:155-162
15. Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, Chin W, Jones J, Woodward A, Le T, Smith C, Smolak P, Goodwin RG, Rauch CT, Schuh JC, Lynch DH 1999 Tumoricidal activity of tumor necrosis factor- related apoptosis-inducing ligand in vivo. Nat Med 5:157-163
16. Mitsiades N, Poulaki V, Tseleni-Balafouta S, Koutras DA, Stamenkovic I 2000 Thyroid carcinoma cells are resistant to FAS-mediated apoptosis but sensitive to tumor necrosis factor-related apoptosis-inducing ligand. Cancer Res 60: 4122-4129
17. Ohta K, Pang XP, Berg L, Hershman JM 1996 Antitumor actions of cytokines on new human papillary thyroid carcinoma cell lines. JClin Endocrinol Metab 81:2607-2612
18. Prabhakar BS, Mulherkar N, Prasad KV 2008 Role of IG20 splice variants in TRAIL resistance. Clin Cancer Res 14:347-351
19. Schievella AR, Chen JH, Graham JR, Lin LL 1997 MADD, a novel death domain protein that interacts with the type 1 tumor necrosis factor receptor and activates mitogen-activated protein kinase. J Biol Chem 272:12069-12075
20. Kurada BRV, Subramanian M, Prasad KV, Prabhakar BS, Essential role for MADD, a prosurvival splice variant of the IG20 gene, in TNFα induced ERK activation. Program of the 99th Annual Meeting of the American Association for Cancer Research, San Diego, CA, 2008, p 425